Novartis’s Radioligand Breakthrough: Market Risks, Competitive Pressures, and Investor Takeaways
Novartis’s new radioligand therapy Pluvicto shows promise yet faces regulatory, cost, and competitive hurdles—analyzing its oncology and immunology pipeline for investors.
5 minutes to read